Aspirin as a cancer fighter? new trial targets colon cancer with PI3K mutation.
NCT ID NCT02945033
First seen Feb 24, 2026 · Last updated May 17, 2026 · Updated 10 times
Summary
This study is for people who had surgery for stage II or III colon cancer with a PI3K mutation. It tests whether taking a low-dose aspirin daily can lower the chance of the cancer returning or a new cancer developing. Half the participants will get aspirin, the other half a placebo, and researchers will track cancer recurrence and survival over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rouen University Hospital
RECRUITINGRouen, France
Contact
Conditions
Explore the condition pages connected to this study.